*JOHNSON & JOHNSON RECEIVES FDA APPROVAL FOR IMAAVY™ (NIPOCALIMAB-AAHU), A NEW FCRN BLOCKER OFFERING LONG-LASTING DISEASE CONTROL IN THE BROADEST POPULATION OF PEOPLE LIVING WITH GENERALIZED MYASTHENIA GRAVIS $(GMG.AU)$
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 30-APR-202512:29:13.7 GMT